Table 1.

Relationship of XIAP protein expression with clinicopathologic parameters in prostate adenocarcinomas

All patientsMean XIAP expression (SE)P (XIAP: continuous variable)*Low XIAP intensity ≤1.8 (% of total)High XIAP intensity >1.8 (% of total)P (XIAP: dichotomized variable)
Total cases (N = 192)1.28 (0.041)158 (82)34 (18)
Age at surgery0.26 (NS)*
    Median (range)65 (46-76)65 (46-76)63.0 (50-75)
    Mean63.864.063.0
Gleason score0.99 (NS)0.31 (NS)
    2-6112 (58)1.28 (0.055)89 (56)23 (68)
    7-1080 (42)1.27 (0.063)69 (44)11 (32)
Pathology pT stage0.63 (NS)0.21 (NS)
    PT2-pT3a158 (82)1.28 (0.046)127 (80)31 (91)
    PT3b34 (18)1.24 (0.092)31 (20)3 (9)
Lymph node status (n = 190)0.47 (NS)>0.99 (NS)
    Positive11 (6)1.12 (0.202)9 (6)2 (6)
    Negative179 (94)1.29 (0.042)147 (94)32 (94)
Surgical margins0.36 (NS)0.55 (NS)
    Positive62 (32)1.22 (0.076)53 (34)9 (26)
    Negative130 (68)1.30 (0.049)105 (66)25 (74)
Capsular involvement0.016§0.11 (NS)
    No invasion40 (21)1.10 (0.094)34 (21)6 (18)
    Invasion113 (59)1.38 (0.052)88 (56)25 (73)
    Extension39 (20)1.16 (0.090)36 (23)3 (9)
Organ confined0.15 (NS)0.15 (NS)
    Yes100 (52)1.33 (0.058)78 (49)22 (65)
    No92 (48)1.22 (0.058)80 (51)12 (35)
High risk (n = 190)0.62 (NS)0.28 (NS)
    Yes38 (20)1.24 (0.090)34 (22)4 (12)
    No152 (80)1.29 (0.046)122 (78)30 (88)
PreOpPSA, ng/mL (n = 172)0.80 (NS)*
    Median (range)9.2 (0.6-96.5)9.8 (0.6-76.0)8.9 (3.2-96.5)
    Mean14.014.014.0
    <1087 (51)1.31 (0.063)0.74 (NS)0.48 (NS)
    ≥1085 (49)1.31 (0.061)
Recurrence**0.082 (NS)††0.0010††
    Yes69 (36)1.18 (0.059)67 (42)2 (6)
    No123 (64)1.33 (0.055)91 (58)32 (94)
Overall follow-up‡‡ (mo)
    Median (range)78.5 (0.1-182.0)74.0 (0.1-182.0)88.5 (6.0-152.0)
    Mean74.572.484.20.085 (NS)*
Total follow-up§§ (mo)
    Median (range)48.5 (0.1-163.0)41.0 (0.1-163.0)87.0 (6.0-152.0)
    Mean52.346.181.3<0.0001*
  • * P value was determined by the Mann-Whitney U test unless otherwise specified.

  • P value was determined by the Pearson χ2 test with Yates continuity correction unless otherwise specified.

  • pT3b indicates seminal vesicle invasion. There are no pT4 cases.

  • § P value was determined by the Kruskal-Wallis test. With capsular involvement as a continuous variable, P = 0.45 using the Spearman correlation corrected for ties.

  • No capsular extension and/or seminal vesicle and/or lymph node involvement. Margins are negative.

  • High-risk seminal vesicle and/or nodal positivity.

  • ** Recurrence PSA elevation raising >0.2 ng/mL status post-radical prostatectomy.

  • †† XIAP mean intensity association with recurrence by logistic regression of continuous data; (P = 0.082; 0.63; 95% confidence interval, 0.37-1.06), and of dichotomized data (P = 0.0010; 11.78; 95% confidence interval, 2.73-50.88). XIAP expression was the independent variable.

  • ‡‡ Overall follow-up time from primary surgery to last PSA follow-up.

  • §§ Total follow-up time to recurrence to last follow-up in nonrecurrence.